Ibogaine Heart Risks: QTc & Arrhythmia Review (Brunt 2026)

Quick answer

Ibogaine is a real heart risk. It can prolong the QTc interval and trigger dangerous ventricular arrhythmias, including torsades de pointes, sometimes at therapeutic doses and in people with no known heart disease. Brunt's 2026 review in *Addiction* says treatment should happen only under controlled medical supervision with rigorous cardiac monitoring. Ibogaine is Schedule I and not approved for any indication.

Definition

Definition: Brunt (2026) in *Addiction* (doi: 10.1111/add.70319; PMID 41560340) is a “Rare but relevant” review/teaching article on ibogaine cardiovascular complications—specifically prolonged QT/QTc and ventricular arrhythmias including Torsades de Pointes (TdP). It explains hERG (and related) channel mechanisms, notes that events can occur at therapeutic doses and even without known pre-existing cardiac disease, highlights CYP2D6 interindividual variability as a risk amplifier, and argues future ibogaine-assisted treatment should occur only under controlled medical supervision with genotyping considerations and rigorous cardiovascular monitoring. This is cardiac safety teaching—not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) efficacy. Ibogaine is U.S. Schedule I and not approved for any indication.

Short answer

Brunt’s 2026 Addiction review explains that ibogaine can prolong QTc and trigger ventricular arrhythmias, including torsades, even at therapeutic doses. CYP2D6 variability may raise risk in some people. Medical supervision and cardiac monitoring are mandatory. The article does not prove psychoactive IV ibogaine infusion efficacy. Ibogaine is not approved for any indication.

Why this paper matters

Primary safety studies (Knuijver) give numbers; AE reviews (Ona) catalog cases; this *Addiction* piece teaches clinicians and families the mechanism → arrhythmia → monitoring story in one place. Next steps: /safety-and-screening → /apply. Mortality: /blog/ibogaine-mortality-cardiac-risk.

What was studied / synthesized

Methods (plain language)

This is not a new n=14 PK trial. It synthesizes mechanistic and clinical literature to explain why ibogaine’s anti-addictive interest collides with a rare-but-serious cardiac toxicity. Teaching reviews are valuable when they keep mechanism, case reality, and monitoring recommendations in the same narrative.

Key findings (no hype)

Themes emphasized:

• Ibogaine/noribogaine can prolong QT/QTc (conventional thresholds often discussed around ≥450 ms men / ≥460 ms women, rate-corrected), impairing cardiac repolarization.
• Delayed repolarization can enable ventricular tachyarrhythmias and TdP, which can be fatal.
• Mechanistic focus includes hERG potassium-channel blockade by ibogaine/noribogaine; additional L-type calcium channel modeling contributions are discussed in the literature.
• Case reports show events at therapeutic doses and in people without known pre-existing cardiac conditions.
• Large CYP2D6 metabolism variability may contribute to higher CV risk in some individuals (ties to Knuijver 2024 PK).
• Safety efforts discussed: dosing strategies, cardiovascular monitoring, and preclinical analogues aiming to retain anti-addictive signals without cardiotoxicity.
• Recommendation: future treatment exclusively under controlled medical supervision with CYP2D6 genotyping considerations and rigorous CV monitoring; trials should evaluate safer analogues and personalized strategies.

Honest reading: “Rare” modifies frequency language—not seriousness. TdP is never a marketing footnote.

Limits and confounders

Route honesty: oral ≠ psychoactive IV

Most human QTc datasets (including Knuijver oral 10 mg/kg) are oral. Intravenous psychoactive delivery changes kinetics but does not cancel hERG biology. Support IV magnesium in oral MISTIC-type protocols is support, not evidence that QTc risk vanished (/blog/magnesium-ibogaine-cardiac-protocol, /blog/ibogaine-oral-vs-iv, /blog/stanford-ibogaine-mistic). IV ibogaine infusion as described on this site still means physician-supervised psychoactive IV with continuous monitoring culture.

Cardiac safety context — practical translation

Deep dives: /blog/knuijver-2021-ibogaine-qtc-safety, /blog/knuijver-2024-ibogaine-pk-cyp2d6, /blog/ibogaine-telemetry-acls-monitoring, /blog/ibogaine-drug-interactions-qtc, /blog/ibogaine-setting-factors-safety-review-2023.

What this does NOT prove for IV ibogaine infusion

U.S. Schedule I / not approved (/blog/is-ibogaine-legal-us).

Next steps

If ventricular arrhythmia language is new to you, do not skip it. Cardiac education first: /safety-and-screening. Only then /apply for physician-supervised IV ibogaine infusion questions. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Brunt Addiction article? A 2026 “Rare but relevant” review on ibogaine-related QTc prolongation and ventricular arrhythmias/TdP.

Can cardiac events happen at therapeutic doses? Yes—review emphasizes reports at therapeutic doses, including in people without known prior cardiac disease.

What mechanism is emphasized? hERG potassium-channel blockade delaying cardiac repolarization (with related channel literature).

Does CYP2D6 matter? Interindividual CYP2D6 variability may contribute to higher cardiovascular risk in some people.

Does this prove IV ibogaine infusion is effective? No. It is cardiac risk teaching, not an efficacy RCT.

Is medical supervision optional? Author argues future treatment should be exclusively under controlled medical supervision with rigorous CV monitoring.

Where should families start? /safety-and-screening.

Is ibogaine approved for medical use? No. Schedule I in the U.S.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Brunt 2026 is cardiovascular complication teaching—not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Brunt T.M. Rare but relevant: Ibogaine and cardiovascular complications—prolonged QT interval and ventricular arrhythmias. *Addiction*. 2026;121(6):1616–1621. doi: 10.1111/add.70319. PMID: 41560340.
2. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
3. Knuijver T. et al. *J Psychopharmacol*. 2024. doi: 10.1177/02698811241237873.
4. Ona G. et al. *Psychopharmacology*. 2022. doi: 10.1007/s00213-021-05964-y.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

How dangerous is ibogaine for the heart?

The honest answer is that serious cardiac events are uncommon but can be fatal, and they are not limited to people with known heart problems. Brunt's review uses the phrase "rare but relevant" for exactly this reason. "Rare" describes how often events are reported. It does not make them less serious. Torsades de pointes is a ventricular arrhythmia that can stop the heart from pumping effectively.

Why does ibogaine prolong the QT interval?

The main mechanism the review describes is hERG potassium-channel blockade by ibogaine and its active metabolite noribogaine. Blocking that channel slows how the heart muscle electrically resets between beats (repolarization). On an ECG, that shows up as a longer QT interval, usually reported as a rate-corrected QTc. A longer QTc opens the door to ventricular tachyarrhythmias and torsades. For measured numbers from a monitored study, see the Knuijver 2021 QTc study.

Who is at higher risk?

• People with a long baseline QTc, structural heart disease or a history of arrhythmia.
• People taking other QT-prolonging medicines or drugs that interact with ibogaine's metabolism (see ibogaine drug interactions).
• People with low potassium or magnesium.
• People whose CYP2D6 metabolism differs from average. The review highlights large person-to-person CYP2D6 variability as a possible risk amplifier.

Having no known heart condition does not mean having no risk. That is one of the review's central teaching points.

How long does the cardiac risk last?

The risk does not end when the acute experience fades. Noribogaine stays in the body longer than ibogaine, and the review's practical message is that monitoring has to cover a delayed window, which is why overnight observation matters. Ask any program how long telemetry continues after dosing and who reads it.

What does good cardiac screening and monitoring look like?

• A baseline 12-lead ECG with a QTc reading and a stated exclusion threshold.
• Electrolyte checks and correction before dosing.
• A full medication review, including CYP2D6 interactions, and a genotype discussion where available.
• Continuous telemetry during and after dosing, with serial ECGs.
• ACLS-trained staff, a defibrillator and a written emergency transfer plan.

The checklist is in the ibogaine ECG checklist, and monitoring standards are in telemetry and ACLS monitoring. Programs serving U.S. patients operate abroad, with intake locations including Mexico and Gabon. The same cardiac standards should apply wherever treatment happens.

Does IV delivery remove the heart risk?

No. Most human QTc data come from oral dosing. Giving ibogaine intravenously changes the kinetics but does not switch off hERG biology. On this site, IV ibogaine infusion means physician-supervised psychoactive IV dosing with continuous cardiac monitoring.

Next step: Read safety and screening (/safety-and-screening) first, then apply confidentially (/apply).